By KATIE THOMAS
Drug makers, insurers and pharmacy benefit managers face mounting pressure from Congress and the public to reduce the high list prices of drugs like insulin.
Published: April 2, 2019 at 08:00PM
from NYT Health https://ift.tt/2FSv7Zc
via IFTTT
from WordPress https://ift.tt/2FKaf6w
via IFTTT
No comments:
Post a Comment